FY2025 EPS Estimate for Aura Biosciences Boosted by Analyst

Aura Biosciences, Inc. (NASDAQ:AURA) – Research analysts at Leerink Partnrs raised their FY2025 earnings per share estimates for Aura Biosciences in a research report issued on Sunday, November 16th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($1.84) per share for the year, up from their previous estimate of ($1.98). The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share. Leerink Partnrs also issued estimates for Aura Biosciences’ Q4 2025 earnings at ($0.45) EPS, FY2026 earnings at ($2.11) EPS and FY2027 earnings at ($2.23) EPS.

Several other research analysts have also issued reports on AURA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aura Biosciences in a research report on Monday. Zacks Research upgraded shares of Aura Biosciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 19th. Finally, HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of Aura Biosciences in a research report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Aura Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $20.50.

Aura Biosciences Stock Performance

AURA stock opened at $5.41 on Wednesday. The company has a market capitalization of $343.54 million, a P/E ratio of -2.79 and a beta of 0.45. The company has a fifty day moving average price of $5.97 and a 200-day moving average price of $6.22. Aura Biosciences has a 52-week low of $4.34 and a 52-week high of $9.53.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.06.

Insiders Place Their Bets

In other news, insider Los Pinos Elisabet De sold 9,049 shares of the company’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $6.35, for a total transaction of $57,461.15. Following the transaction, the insider owned 474,391 shares in the company, valued at approximately $3,012,382.85. This represents a 1.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Janet Jill Hopkins sold 17,109 shares of the stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $5.42, for a total transaction of $92,730.78. Following the transaction, the insider directly owned 252,685 shares in the company, valued at $1,369,552.70. This trade represents a 6.34% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 39,223 shares of company stock worth $233,155. Corporate insiders own 6.30% of the company’s stock.

Institutional Investors Weigh In On Aura Biosciences

A number of hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its position in shares of Aura Biosciences by 49.3% during the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock worth $40,000 after purchasing an additional 2,104 shares during the period. Water Island Capital LLC acquired a new position in Aura Biosciences during the third quarter worth $64,000. 49 Wealth Management LLC bought a new position in shares of Aura Biosciences in the third quarter valued at $66,000. Invesco Ltd. acquired a new position in shares of Aura Biosciences during the second quarter valued at about $76,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Aura Biosciences by 24.3% during the second quarter. China Universal Asset Management Co. Ltd. now owns 12,453 shares of the company’s stock worth $78,000 after acquiring an additional 2,434 shares in the last quarter. Institutional investors and hedge funds own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.